{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:52:40Z","timestamp":1774569160131,"version":"3.50.1"},"reference-count":15,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: This retrospective one-center study demonstrates the complications related to high-dose therapy with autologous stem cell support (HDT) and the survival of multiple myeloma (MM) patients according to age groups. Methods: We categorized the patients into two groups: those who were \u226465 years old (group 1) (N = 115) and those who were &gt;65 years old (group 2) (N = 26). The mean duration of follow-up was 48 (1\u2013125) months. Results: In group 2 patients, the use of a reduced dosage of melphalan (12 [46%] versus 30 [26%]) was more frequent in comparison to group 1 (p = 0.046). There was a statistically significant difference between the two groups regarding the neutrophil engraftment days (p = 0.001) and the median progression-free survival (PFS) (p = 0.02). The PFS was 44 months for group 1 and 30 months for group 2. There was no statistically significant difference between the groups in relation to the median duration of hospitalization, presence of bacteremia, intravenous antibiotic administration, and overall survival (OS). Conclusions: The study\u2019s results indicate that HDT is a reliable method of treatment for older patients with MM, provided that they obtain a suitable conditioning regimen and, furthermore, these patients achieved a comparable OS rate to that of younger patients.<\/jats:p>","DOI":"10.3390\/jcm13144142","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:12:49Z","timestamp":1721128369000},"page":"4142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Age on High-Dose Therapy with Autologous Stem Cell Support in Multiple Myeloma: A Single-Center Experience"],"prefix":"10.3390","volume":"13","author":[{"given":"Elcin","family":"Erdogan Yucel","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Health Science, Izmir City Hospital, 35180 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Tugce","family":"Kirmaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Kakci","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin Fatma","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugce","family":"Sencelikel","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Medipol University, Ankara 34810, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inci","family":"Alacacioglu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guner Hayri","family":"Ozsan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eylul University, 35220 Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation versus Bortezomib\u2013Melphalan\u2013Prednisone, with or without Bortezomib\u2013Lenalidomide\u2013Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02\/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.13804","article-title":"Autologous Stem Cell Transplantation in Multiple Myeloma Patients over 70 Years: AGIMEMALazio Working Group Experience in a Retrospective Case\u2013Control Study","volume":"109","author":"Rago","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41409-020-01026-7","article-title":"Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma","volume":"56","author":"Lemieux","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bmt.1704288","article-title":"Autologous stem cell transplantation in multiple myeloma patients <60 vs \u226560 years of age","volume":"32","author":"Reece","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10,549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.htct.2020.06.014","article-title":"Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma","volume":"43","author":"Bove","year":"2021","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: Exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2020","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-018-3528-x","article-title":"Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"98","author":"Marini","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00277-019-03878-6","article-title":"Real-word data on autologous stem cell transplantation in older patients with multiple myeloma","volume":"99","author":"Schain","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as Postinduction Maintenance for Patients with Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma (MAIA): Overall Survival Results from a Randomised, Open-Label, Phase 3 Trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation","volume":"82","author":"Nath","year":"2016","journal-title":"BJCP. Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3324\/haematol.2022.281020","article-title":"Autologous stem cell transplantation in an older adult population","volume":"107","author":"Fedorov","year":"2022","journal-title":"Haematologica"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/4142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:17:28Z","timestamp":1760109448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/4142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":15,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13144142"],"URL":"https:\/\/doi.org\/10.3390\/jcm13144142","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]}}}